Methods for treating immune system diseases using a soluble CTLA4 molecule
First Claim
Patent Images
1. A method of treating a subject having rheumatoid arthritis, wherein the subject has failed at least one Disease Modifying Antirheumatic Drug (DMARD), comprising administering an effective amount of a soluble CTLA4 fusion molecule comprising an extracellular domain of a CTLA4 molecule, wherein the extracellular domain of the CTLA4 molecule comprises the amino acids shown in SEQ ID NO:
- 17 beginning with methionine at position +27 or with alanine at position +26 and ending with aspartic acid at position +150.
3 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to compositions and methods for treating rheumatic disease by administering to a subject, soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands.
-
Citations
31 Claims
-
1. A method of treating a subject having rheumatoid arthritis, wherein the subject has failed at least one Disease Modifying Antirheumatic Drug (DMARD), comprising administering an effective amount of a soluble CTLA4 fusion molecule comprising an extracellular domain of a CTLA4 molecule, wherein the extracellular domain of the CTLA4 molecule comprises the amino acids shown in SEQ ID NO:
- 17 beginning with methionine at position +27 or with alanine at position +26 and ending with aspartic acid at position +150.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 24, 25, 26, 27, 28, 29, 30)
- 14. The method of 13, wherein the non- CTLA4 molecule comprises an amino acid sequence which alters the solubility or affinity of the soluble CTLA4 fusion molecule.
-
21. A method for reducing or preventing structural damage in a subject having a rheumatic disease comprising administering an effective amount of a soluble CTLA4 fusion molecule comprising an extracellular domain of a CTLA4 molecule, wherein the extracellular domain of the CTLA4 molecule comprises the amino acids shown in SEQ ID NO:
- 17 beginning with methionine at position +27 or with alanine at position +26 and ending with aspartic acid at position +150.
- View Dependent Claims (22, 23, 31)
Specification